EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Effectiveness of Cell Culture-Based Influenza Vaccine, 2023-2024

Huong Q Nguyen iD, Oluwakemi D Alonge iD, Kayla E Hanson iD, Elisha Stefanski, Joshua G Petrie iD, Karita Ambrose, Ashesh Gandhi, Adam Bissonnette, Gregg C Sylvester, Jennifer K Meece, Edward A Belongia iD

Journal of the Pediatric Infectious Diseases Society · 2025

DOI: 10.1093/jpids/piaf069 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Pediatric Infectious Diseases Society, 2025. Verfasst von Huong Q Nguyen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, WI, United States. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human, Vaccine Efficacy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CSL Seqirus.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The cell culture-based inactivated influenza vaccine (ccIIV) was first approved for use in children aged 4-17 years in 2016 in the United States. The approved age indication for ccIIV was expanded to include children 6 months and older beginning the 2022-2023 season. There is limited real-world data on ccIIV effectiveness in children. We assessed ccIIV effectiveness using the test-negative design during the 2023-2024 season.

Methods

Patients aged 6 months to 64 years who sought outpatient or telehealth care for acute respiratory illness were actively recruited between October 2023 and May 2024. Symptom eligibility criteria included cough, with an illness duration of ≤ 7 days. Respiratory samples were tested by reverse transcription polymerase chain reaction to identify influenza cases. Vaccination dates and products were determined by immunization records. Analyses were restricted to ccIIV recipients and unvaccinated participants. Cell culture-based inactivated influenza vaccine effectiveness was estimated as [100% × (1 − odds ratio)] for vaccination in cases versus test-negative controls, with adjustment for age and calendar time.

Results

Among 1850 participants, 12% were age 6 months to 3 years, 32% were age 4-17 years, and 56% were age 18-64 years. Influenza was detected in 505 (27%) participants; 267 had influenza A/H1N1pdm09; 149 had influenza B; 56 had influenza A/H3N2; and 33 had influenza A with unknown subtype. A total of 470 (25%) received ccIIV. Among children (age 6 months to 17 years), ccIIV effectiveness was 64% [95% confidence interval (CI), 37%-81%] against influenza A/H1N1pdm09, 75% (95% CI, 43%-91%) against influenza B, and 76% (95% CI, 4%-97%) against influenza A/H3N2. Among adults (age 18-64 years), ccIIV effectiveness was 56% (95% CI, 31%-73%) against influenza A/H1N1pdm09, 62% (95% CI, 13%-86%) against influenza B, and 33% (95% CI, −62% to 76%) against influenza A/H3N2. Young children aged 6 months to 3 years had the highest point estimates (88%-98%).

Conclusion

Cell culture-based inactivated influenza vaccine generated substantial real-world effectiveness against medically attended, laboratory-confirmed influenza in children and adults during a season when influenza A/H1N1pdm09 viruses predominated and influenza B and influenza A/H3N2 co-circulated at lower levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesInfluenza, HumanVaccine EfficacyHumansAdolescentChildChild, PreschoolAdultMiddle AgedMaleYoung AdultFemaleInfantVaccines, InactivatedInfluenza A Virus, H1N1 SubtypeUnited StatesInfluenza A Virus, H3N2 SubtypeCell Culture TechniquesInfluenza B virus

Stichwörter der Autor:innen

cell-based influenza vaccineinfluenzapediatricvaccine effectiveness

Substanzen

Influenza VaccinesVaccines, Inactivated

Autor:innen und Institutionen

  • Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, WI, United States.
  • Medical Affairs, CSL Seqirus, Summit, NJ, United States.
  • Integrated Research and Development Laboratory, Marshfield Clinic Research Institute, Marshfield, WI, United States.

ORCID-Profile: Huong Q Nguyen, Oluwakemi D Alonge, Kayla E Hanson, Joshua G Petrie, Edward A Belongia

Förderung

  • CSL Seqirus

Zitieren

APA

Nguyen, H. Q., Alonge, O. D., Hanson, K. E., Stefanski, E., Petrie, J. G., Ambrose, K., Gandhi, A., Bissonnette, A., Sylvester, G. C., Meece, J. K., & Belongia, E. A. (2025). Effectiveness of Cell Culture-Based Influenza Vaccine, 2023-2024. Journal of the Pediatric Infectious Diseases Society. https://doi.org/10.1093/jpids/piaf069

Vancouver

Nguyen HQ, Alonge OD, Hanson KE, Stefanski E, Petrie JG, Ambrose K, et al. Effectiveness of Cell Culture-Based Influenza Vaccine, 2023-2024. Journal of the Pediatric Infectious Diseases Society. 2025. doi:10.1093/jpids/piaf069

BibTeX
@article{Nguyen2025,
  author = {Nguyen, Huong Q and Alonge, Oluwakemi D and Hanson, Kayla E and Stefanski, Elisha and Petrie, Joshua G and Ambrose, Karita and Gandhi, Ashesh and Bissonnette, Adam and Sylvester, Gregg C and Meece, Jennifer K and Belongia, Edward A},
  title = {Effectiveness of Cell Culture-Based Influenza Vaccine, 2023-2024},
  journal = {Journal of the Pediatric Infectious Diseases Society},
  year = {2025},
  doi = {10.1093/jpids/piaf069}
}
Kostenlos starten →